
EC grants marketing authorization to epcoritamab combo in second-line FL
The European Commission has granted marketing authorization to epcoritamab (TEPKINLY® ) in combination with rituximab and lenalidomide (R2) for the treatment of relapsed or refractory follicular lymphoma in the second-line setting.




